Holen Sie sich die Stockscreener-App
184.52
2.30%
-4.35
Handel nachbörslich:
184.52
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$188.87
Offen:
$187.8
24-Stunden-Volumen:
172.74K
Relative Volume:
0.78
Marktkapitalisierung:
$3.62B
Einnahmen:
$152.42M
Nettoeinkommen (Verlust:
$45.24M
KGV:
73.51
EPS:
2.51
Netto-Cashflow:
$6.97M
1W Leistung:
-0.57%
1M Leistung:
+6.58%
6M Leistung:
+65.67%
1J Leistung:
+59.72%
1-Tages-Spanne:
$182.87
$191.88
1-Wochen-Bereich:
$182.87
$194.44
52-Wochen-Spanne:
$93.58
$194.44
Ligand Pharmaceuticals Inc Stock (LGND) Company Profile
Firmenname
Ligand Pharmaceuticals Inc
Sektor
Branche
Telefon
858-550-7500
Adresse
3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
Vergleichen Sie LGND mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LGND
Ligand Pharmaceuticals Inc
|
184.52 | 3.68B | 152.42M | 45.24M | 6.97M | 2.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
417.21 | 108.30B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
652.91 | 69.37B | 14.25B | 4.58B | 3.56B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.59 | 62.38B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
821.97 | 51.50B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
166.95 | 34.94B | 398.11M | -1.03B | -868.57M | -5.7032 |
Ligand Pharmaceuticals Inc Stock (LGND) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-10 | Eingeleitet | Stifel | Buy |
| 2024-10-03 | Eingeleitet | Oppenheimer | Outperform |
| 2024-07-30 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-04-14 | Fortgesetzt | Stephens | Overweight |
| 2021-02-04 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-06 | Eingeleitet | Barclays | Overweight |
| 2020-03-24 | Herabstufung | Argus | Buy → Hold |
| 2020-03-10 | Eingeleitet | Guggenheim | Neutral |
| 2020-02-06 | Eingeleitet | The Benchmark Company | Buy |
| 2019-09-19 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-06-11 | Eingeleitet | Barclays | Equal Weight |
| 2019-05-03 | Bestätigt | H.C. Wainwright | Buy |
| 2019-03-06 | Bestätigt | H.C. Wainwright | Buy |
| 2018-10-29 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2018-10-02 | Bestätigt | H.C. Wainwright | Buy |
| 2018-09-11 | Bestätigt | Argus | Buy |
| 2018-08-17 | Eingeleitet | Goldman | Neutral |
| 2018-08-08 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2018-06-21 | Eingeleitet | Argus | Buy |
| 2017-12-27 | Bestätigt | H.C. Wainwright | Buy |
| 2017-09-05 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-10-05 | Bestätigt | H.C. Wainwright | Buy |
| 2016-08-05 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2016-03-11 | Eingeleitet | Sidoti | Buy |
| 2016-03-03 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Ligand Pharmaceuticals Inc Aktie (LGND) Neueste Nachrichten
Ligand Pharmaceuticals Reaches Analyst Target Price - Nasdaq
Is Ligand Pharmaceuticals Incorporated (LGDN) stock attractive post correctionStock Surge & Free High Accuracy Swing Entry Alerts - newser.com
What institutional flow reveals about Ligand Pharmaceuticals IncorporatedWeekly Market Outlook & Free Weekly Chart Analysis and Trade Guides - newser.com
Intraday pattern recognizer results for Ligand Pharmaceuticals IncorporatedJuly 2025 Outlook & Daily Momentum Trading Reports - newser.com
Short interest data insights for Ligand Pharmaceuticals Incorporated2025 Breakouts & Breakdowns & Risk Controlled Stock Alerts - newser.com
What catalysts could drive Ligand Pharmaceuticals Incorporated stock higherPortfolio Value Report & Low Risk High Win Rate Stock Picks - newser.com
Can Ligand Pharmaceuticals Incorporated stock sustain market leadership2025 Market Overview & Weekly High Return Opportunities - newser.com
What analyst consensus says on Ligand Pharmaceuticals Incorporated stockWeekly Risk Summary & Free Daily Entry Point Trade Alerts - newser.com
Can technical indicators confirm Ligand Pharmaceuticals Incorporated’s reversalQuarterly Market Review & Community Consensus Trade Signals - newser.com
Why Ligand Pharmaceuticals Incorporated stock is a value investor pickJuly 2025 Chart Watch & Real-Time Stock Entry Alerts - Fundação Cultural do Pará
How to use Fibonacci retracement on Ligand Pharmaceuticals IncorporatedQuarterly Profit Review & Verified Momentum Watchlists - newser.com
Technical signs of recovery in Ligand Pharmaceuticals IncorporatedPortfolio Update Summary & Verified High Yield Trade Plans - newser.com
Is Ligand Pharmaceuticals Incorporated reversing from oversold territoryStop Loss & Intraday High Probability Setup Alerts - newser.com
Does Ligand Pharmaceuticals Incorporated show high probability of reboundJuly 2025 Review & Weekly High Potential Alerts - newser.com
Published on: 2025-10-28 01:03:19 - newser.com
How Ligand Pharmaceuticals Incorporated (LGDN) stock compares with market leadersCPI Data & Daily Oversold Bounce Ideas - newser.com
Analyzing drawdowns of Ligand Pharmaceuticals Incorporated with statistical tools2025 Macro Impact & Low Risk Entry Point Tips - newser.com
Ligand Pharmaceuticals Incorporated stock daily chart insightsWeekly Profit Report & Community Driven Trade Alerts - newser.com
Will Ligand Pharmaceuticals Incorporated outperform the market2025 Trading Recap & Risk Controlled Swing Alerts - newser.com
Price action breakdown for Ligand Pharmaceuticals IncorporatedJuly 2025 Summary & Daily Stock Trend Reports - newser.com
Is Ligand Pharmaceuticals Incorporated forming a reversal patternPortfolio Growth Summary & High Accuracy Swing Entry Alerts - newser.com
Chart overlay techniques for tracking Ligand Pharmaceuticals IncorporatedWeekly Trade Analysis & Low Volatility Stock Recommendations - newser.com
Is Ligand Pharmaceuticals Incorporated a good long term investmentRetail Trading Trends & Beat the Market with AI Reports - earlytimes.in
Published on: 2025-10-26 22:30:09 - newser.com
Finanzdaten der Ligand Pharmaceuticals Inc-Aktie (LGND)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.71%
1.60%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):